



Senator Harry Reid  
Senate Majority Leader  
United States Senate  
Washington, D.C

Senator Mitch McConnell  
Senate Minority Leader  
United States Senate  
Washington, D.C.

Dear Senators:

The Israel Life Sciences Institute (ILSI) consists of 1,000 small companies that are producing new creations in the fields of pharmaceuticals, bio-med developments and medical devices. Virtually all of these innovators depend on strong U.S. patents as a foundation for raising capital and ultimately to defend their creations against infringement, piracy and counterfeiting.

We are greatly concerned about the patent legislation now being considered in the U.S. Congress. This legislation would change the way that damages are calculated in infringement lawsuits in a way that is adverse to patent holders. The proposed new post-grant review system would, we fear, result in more lawsuits and would give patent predators a new means to extort patent holders with a threat of legal action. Finally, the proposed Applicant Quality Submission (AQS) would impose substantial new costs on patent applicants that would result in less innovation. These changes will harm Israelis' ability to attract new capital for start-ups and their capacity to create new jobs. The Members of ILSI are creating innovations that in prior ages would be considered miracles. Certainly, they are helping millions of people worldwide.

My request of you is that this legislation not be enacted before its effect on Israeli's patent-dependent sectors are considered.

With best regards.

Dr. Raphael Hofstein  
CEO

